From Data to Dialogue: The 2025 MARIN Payer Report Enhanced by Expert Insights

From Data to Dialogue: The 2025 MARIN Payer Report Enhanced by Expert Insights

In the 2025 Payer Oncology Trend Report, we analyze how health plans and PBMs are navigating the shifting landscape of branded cancer drug management. To deepen our findings, we spoke with industry experts Michael Kolodziej, MD, and Ira Klein, Vice President, Medical Affairs & Payer Relations at Tempus, who shared their perspectives on the data, key trends, and what these insights mean for manufacturers moving forward.

2024 Rewind: Most Memorable Quotes and Insights

In this episode, MAI team members share thought-provoking quotes and insights gathered from conversations this year with key decision makers involved with IDNs, Community Oncology Practices, Payers & Pathways.

Part 3: Community Oncology Practice Economics – Emerging Models for Success

In part 3 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—conclude their conversation on oncology practice economics, discussing emerging models for success (e.g., utilization of advanced therapies) and manufacturer implications.

Part 2: Community Oncology Practice Economics – Operational Realities

In part 2 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—continue their exploration of oncology practice economics, focusing on practices’ operational realities.

Part 1: Community Oncology Practice Economics – Current State

In part 1 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider. and oncology strategist—explore the current state of oncology practice economics.